CRBU

Caribou Biosciences is a clinical-stage biopharmaceutical company developing allogeneic CAR-T cell therapies for hematologic malignancies using its proprietary chRDNA genome-editing technology. The company's lead programs are vispacabtagene regedleucel (vispa-cel), an anti-CD19 CAR-T cell therapy in Phase 1 development for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an anti-BCMA CAR-T cell therapy in Phase 1 development for relapsed or refractory multiple myeloma. Vispa-cel has received RMAT designation, fast track designation, and orphan drug designation from the FDA, while CB-011 has received fast track and orphan drug designations.

Pipeline

Catalyst Calendar